Sigyn Therapeutics (SIGY) Net Margin (2017 - 2020)

Sigyn Therapeutics (SIGY) posted Net Margin of 7720.14% for Q3 2020, up 76.76% sequentially from 33225.13% in Q1 2020.

Sigyn Therapeutics (SIGY) Net Margin (2017 - 2020) Analysis & Trends

Sigyn Therapeutics has reported Net Margin for 4 years, with the latest figure at 7720.14% in Q3 2020.

Quarterly Net Margin changed N/A year-over-year to 7720.14% in Q3 2020, while the trailing twelve-month figure through Sep 2020 was 8133.43% (down 816869.0% YoY) and the FY2019 annual result came in at 166.28%, up 127746.0% from the prior year.
Net Margin advanced to 7720.14% in Q3 2020 per SIGY's latest filing, from 33225.13% in the prior quarter.
Over five years, Net Margin peaked at 531000.0% in Q4 2018 and troughed at 33225.13% in Q1 2020.
A 4-year average of 43937.1% and a median of 228.28% in 2017 frame the typical range for Net Margin.
The sharpest annual moves came in 2018 and 2020: Net Margin surged 53091666 bps in 2018, then slumped 3335499 bps in 2020.
Over 4 years, Net Margin stood at 83.34% in 2017, then jumped by 637022 bps to 531000.0% in 2018, then tumbled by 100 bps to 129.86% in 2019, then sank by 6045 bps to 7720.14% in 2020.
According to Business Quant data, Net Margin over the past three periods registered 7720.14%, 33225.13%, and 129.86% for Q3 2020, Q1 2020, and Q1 2019 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	30.23%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	31.16%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	12.74%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-16.51%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-3.12%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	12.09%
10	Sigyn Therapeutics	48,161.31	-37,409.69	-	-

Download Data